Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

<b>Background/Objectives:</b> Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeutic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-crosslinked hyaluronic acid (HA) as a simple, versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. <b>Methods:</b> Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1<sup>®</sup> (RD1) solutions of varying concentrations were prepared and applied to various in vitro models. Cell viability, proliferation, migration, and collagen stimulation were assessed using standard assays. Additionally, cells were suspended in Redensity 1 and applied to an in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue reformation. <b>Results:</b> Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration, and collagen deposition. Histological analysis revealed improved cell adhesion and migration. <b>Conclusions:</b> This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-12-23
DOI
https://doi.org/10.3390/pharmaceutics18010021
Citations
1
Primary Topic
Wound Healing and Treatments
Type
article
Field-Weighted Citation Impact
1.03
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

Killian Flégeau, Romain Brusini, Jimmy Faivre, Nathalie Hirt-Burri et al.
1 citations
Pharmaceutics
Wound Healing and Treatments
1.03
article

Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

Killian Flégeau, Romain Brusini, Jimmy Faivre, Nathalie Hirt-Burri, Xi Chen, Zhifeng Liao, Lee Ann Applegate
article en
1 citations

Abstract

<b>Background/Objectives:</b> Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeutic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-crosslinked hyaluronic acid (HA) as a simple, versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. <b>Methods:</b> Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1<sup>®</sup> (RD1) solutions of varying concentrations were prepared and applied to various in vitro models. Cell viability, proliferation, migration, and collagen stimulation were assessed using standard assays. Additionally, cells were suspended in Redensity 1 and applied to an in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue reformation. <b>Results:</b> Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration, and collagen deposition. Histological analysis revealed improved cell adhesion and migration. <b>Conclusions:</b> This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.

PharmaceuticsVol. 18(1)
Université Claude Bernard Lyon 1 (FR), University of Zurich (CH), Charles Humbert 8 (CH), University of Lausanne (CH)
Good health and well-being
Openalex Percentile: Top 16%
Wound Healing and Treatments
1.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.